Emma has extensive technical knowledge of DNA and tissue based biomarker testing for precision medicine development from evaluations in early phase clinical studies to regulated diagnostic testing in late phase development.

As an experienced project manager, with excellent communication skills, Emma can drive forward client’s projects, work with external Dx providers and CROs, to support the clinical development of precision medicines. Emma is process driven ensuring robust practices are in place to deliver high quality, reliable clinical biomarker results.

With over 15 years’ experience in the pharmaceutical industry, Emma has a track record delivering robust and practical solutions to the many varied challenges faced through the different stages of drug discovery and precision medicine development.